Douglas W Sborov, MD

Biography

Douglas Sborov, MD MS is an Associate Professor at the University of Utah (UU) – Huntsman Cancer Institute (HCI), Department of Internal Medicine - Division of Hematology and Hematologic Malignancies and Adjunct Associate Professor of Molecular Pharmaceutics. He is the Director of the HCI Hematology Disease Center and Plasma Cell Dyscrasias (PCD) Program, Co-Leader of the Hematologic Malignancies Clinical Trials Research Group, and member of the HCI Experimental Therapeutics Program and International Myeloma Working Group (IMWG). He is an elected Huntsman Translational Scholar, member of the Alliance Myeloma Committee, Society of Medical Oncology (SUMO) Board member, and member of the American Society of Hematology (ASH) Foundation and Communications Committees. Dr. Sborov’s research is focused on investigating novel targeted and immunologic therapies for patients with multiple myeloma and he is the principal investigator of a multiple of trials in patients with plasma cell dyscrasias and is actively involved in early drug development and other translational collaborations. Dr. Sborov is working closely with the entire multiple myeloma team to further develop a state-of-the-art clinical trial and research program that offers patients the opportunity to take part in advancing cutting edge, high quality, next generation treatment options.